EMA Authorised: Pazenir (paclitaxel) — ratiopharm GmbH

View source ↗

Summary

Pazenir (paclitaxel) has been authorised by EMA for use in breast cancer, with ratiopharm GmbH as the Marketing Authorisation Holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pazenir (paclitaxel)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: ratiopharm GmbH. Decision date: 19/06/2025